Plasma Therapy Market Size

Plasma Therapy Market Size Snapshot

Note – Market size depicts the revenue generated over the financial year

The market for the treatment of psoriasis is expected to reach $ 4.8 billion in 2024 and will reach $12.8 billion by 2035. The CAGR for this market is 9.26% from 2025 to 2035. This growth is due to the increasing occurrence of chronic diseases and the increasing demand for more effective treatments. The development of extraction and processing techniques for blood components is also contributing to this growth and will lead to more effective and efficient treatments. The major players in the market, such as Grifols, CSL Behring and Takeda, are investing heavily in research and development to improve their products and thus patient outcomes. Strategic initiatives, such as the creation of associations and alliances, aimed at increasing the distribution network and the product range, are also accelerating this growth. Recent product launches and innovations in blood-based therapies, for example, are expected to meet the growing demand and improve the efficacy of treatments, thus strengthening the market's positive outlook in the coming years.

Regional Market Size

Regional Deep Dive

The market for blood and plasma therapy is experiencing significant growth across the globe, owing to the increasing awareness about regenerative medicine and the technological advancements. In North America, the market is characterized by the high adoption of novel therapies and the robust healthcare system. Europe is characterized by a varied regulatory framework, which influences the market dynamics. The Asia-Pacific region is characterized by a rapid rise in the healthcare expenditure and the growing patient population. Middle East and Africa (MEA) are adopting the use of blood and plasma therapy slowly, owing to the increasing investments in the healthcare industry. Latin America is also emerging as a potential market, owing to the growing demand for novel therapies and the increasing focus on the advancements in the healthcare industry.

North America

• The Federal Food and Drug Administration has recently shortened the time it takes to get approval for certain plasma-derived medicines, thus encouraging innovation and allowing new products to enter the market more quickly.
• In the meantime, the major players, Grifols and CSL Behring, are increasing their production capacities in the region, in response to the growing demand for the products of the blood.
• In the United States, the trend toward individualized medicine is leading to an increase in research and development of tailored therapies based on the use of blood.

Europe

• The European Medicines Agency has issued new guidelines for the use of plasma therapies which are intended to enhance safety and efficacy in all member states.
• In Europe, projects such as the European Union's Plasma for Life initiative are focused on improving the collection and processing of blood components.
• Germany and France, where the public is more receptive to alternative medicine, have embraced the use of plasma in the treatment of skin disorders.

Asia-Pacific

• In the Far East, where the average income is rising, there are a growing number of plasma therapy clinics.
• The Australian government has initiated a programme to encourage research in the field of blood therapy, and to promote collaboration between the academic institutions and the industry.
• Japan is expected to boost the growth of the plasma therapy market with the government's active support for the development of new products.

MEA

• The United Arab Emirates has recently begun a series of reforms in health care aimed at improving the quality of medical services. These reforms include the promotion of the use of blood-clotting therapies.
• The development of new therapies based on blood components has begun, and the hospital is collaborating with the international biotechnological companies.
• Culture and the growing acceptance of modern medicine are influencing the gradual introduction of the new therapy.

Latin America

• Brazil is witnessing a boom in clinical trials for the use of blood plasma, thanks to government initiatives aimed at promoting innovation in the health sector.
• The companies of the country are beginning to invest in the establishment of collection centres to meet the growing demand for these treatments.
• Latin America, as in other parts of the world, is suffering from an increase in chronic illnesses, and as a result the demand for new treatment methods, including plasma therapy, is on the increase.

Did You Know?

“In the fields of medicine, mainly orthopedics, dermatology and dentistry, the versatility of the method has been shown.” — American Academy of Orthopaedic Surgeons

Segmental Market Size

The world market for blood plasma products is growing fast, mainly due to the increasing awareness of regenerative medicine and the healing properties of blood-derived products. The growing number of chronic diseases, which need new treatment methods, and the development of medical technology, which facilitates the use of blood plasma, are the main reasons for the growing demand. In addition, supportive regulatory frameworks in the United States and Europe facilitate the market expansion by simplifying the approval of new therapies.

Today, the use of plasma therapies is at a mature stage, with Grifols and CSL Behring being active in implementing the therapies in a variety of clinical settings. These therapies are primarily used in the treatment of haemophilia and immune deficiency, and their role in patient care is becoming increasingly important. The trend towards a more individualised approach to medicine and the growing emphasis on minimally invasive procedures will also bring about a further increase in interest in these therapies. In terms of the future, apheresis and advanced bioprocessing are shaping the development of this segment, ensuring that the quality and productivity of the products are maintained.

Future Outlook

The market for plasma therapy is projected to grow at a CAGR of 9.26% between 2024 and 2035. This growth is driven by the increasing acceptance of plasma-derived therapies in various medical fields, such as orthopedics, dermatology, and sports medicine. Consequently, the penetration of these therapies in these medical fields is expected to increase significantly, and it is estimated that penetration in 2035 will exceed 30%.

Extraction methods and improved processing methods are likely to drive market growth in the coming years. In addition, the development of point-of-care devices and the development of personalized therapies will also play an important role in the expansion of the market. In addition, favorable regulatory frameworks and increased funding for regenerative medicine research and development will further promote the development of the market. The trend of integrating PTT with other therapies and the development of minimally invasive procedures will also promote the development of the market.